CN1066332C - Hypoglycemic compound capsule - Google Patents

Hypoglycemic compound capsule Download PDF

Info

Publication number
CN1066332C
CN1066332C CN94101219A CN94101219A CN1066332C CN 1066332 C CN1066332 C CN 1066332C CN 94101219 A CN94101219 A CN 94101219A CN 94101219 A CN94101219 A CN 94101219A CN 1066332 C CN1066332 C CN 1066332C
Authority
CN
China
Prior art keywords
present
radix
diabetes
effect
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN94101219A
Other languages
Chinese (zh)
Other versions
CN1107711A (en
Inventor
彭建玉
高庆川
牛炳祥
尹志远
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baishan Tang Wei (Cangzhou) Pharmaceutical Co. Ltd.
Original Assignee
CANGZHOU CHINESE-MEDICINAL PHARMACEUTICAL FACTORY HEBEI PROV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CANGZHOU CHINESE-MEDICINAL PHARMACEUTICAL FACTORY HEBEI PROV filed Critical CANGZHOU CHINESE-MEDICINAL PHARMACEUTICAL FACTORY HEBEI PROV
Priority to CN94101219A priority Critical patent/CN1066332C/en
Publication of CN1107711A publication Critical patent/CN1107711A/en
Application granted granted Critical
Publication of CN1066332C publication Critical patent/CN1066332C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

The present invention relates to a Tangwei capsule for treating diabetes, which belongs to a Chinese and western compound medicine. The present invention applies a Chinese medicine theory, adopts a principle for treating both manifestation and root reasons of diseases, and achieves the purposes for rapidly relieving and eliminating symptoms of diabetes by regulating physiological functions of organs of a human body, and furthermore, the present invention reduces blood sugar and urine glucose, and the poison side effect is little. The present invention comprises the following proportions of the prescription (the weight percentages): 3 to 10% of American ginseng, 10 to 40% of coptis, 10 to 40% of astragalus roots, 10 to 40% of red sage roots, 5 to 30% of pueraria roots, 10 to 30% of solomonseal rhizome and 10 to 30% of radices trichosanthis, and furthermore, the present invention contains 2.5-15 mgglyburide (the dosage of a day). The treatment effect on reducing blood sugar of the medicine of the present invention is obviously superior to that of a comparison group of Youjiangtang and Xiaokewan by 120 cases of system clinical observation, the treatment display rate reaches 54.17%, and the total effective rate reaches 95%. The present invention has the characteristics of rapid effect, strong action, high treatment effect, less poison side effect and rapid symptom elimination.

Description

Hypoglycemic compound capsule
The present invention relates to a kind of hypoglycemic compound capsule for the treatment of diabetes, belong to the Chinese medicine and western medicine compound preparation.
Diabetes are a kind of common whole body chronic progressive disease.Because pancreatic is excreting insulin normally, cause insulin relative or absolute not enough, cause sugar, fat, proteinic metabolism disorder, hepatic glycogen and muscle glycogen can not be synthesized.Thereby occurred that blood glucose, glucose in urine raise and carbohydrate tolerance reduces, and typical clinical symptom is polydipsia, polyphagia, polyuria, lose weight etc., " three-many-one-little " symptom, the traditional Chinese medical science claim that diabetes are diabetes." more than three " are " three types of diabetes ".The damage of lung, stomach, kidney is the basis, sick position of diabetes, and the metabolism disorder of water liquid is the material base of diabetes.Diabetic duration length, easy concurrent whole body nerve, blood capillary, macroangiopathy are the more serious endocrine-metabolic diseases of harmful to human.Along with improving constantly of people's living standard, the change of dietary structure, the reduction of labor intensity is swashing increasing of state, and its sickness rate is rising gradually.The sickness rate of diabetes is 3-5% in the world, be about 0.7-1% according to China's incomplete statistics, the city is significantly higher than the rural area, interrelated data shows, at present the mortality rate that is caused by diabetes is higher, be only second to diseases such as cardiovascular, cerebrovascular and tumor, therefore positive prevention and treatment diabetes seem very important.The medicine for the treatment of at present diabetes clinically is a lot, can be divided into Western medicine and Chinese medicine two classes basically, and the oral western medicine majority can be than blood sugar lowering faster, but is prone to side effect such as hypoglycemic reaction, gastrointestinal reaction, and eliminates slower to the symptom of diabetes.The symptom of diabetes can be alleviated and eliminate to the Chinese medicine majority preferably, and toxic and side effects is less, but blood sugar lowering, glucose in urine are slower.Make a general survey of now clinical commonly used in, western drug, all do not reach promptly rapid-action, effect is strong, curative effect is high, toxic and side effects is little, symptom is eliminated fast characteristics.
The object of the present invention is to provide a kind ofly can reach rapid-action to treatment of diabetes, effect is strong, curative effect is high, toxic and side effects is little, symptom is eliminated fast Chinese medicine and western medicine compound preparation-hypoglycemic compound capsule.
The object of the present invention is achieved like this, and it is the application theory of Chinese medical science, adopts the principle for the treatment of both the principal and secondary aspects of a disease, and by adjusting the physiological function of each internal organs of body, reach rapid alleviation and eliminate diabetic symptom, blood sugar lowering, glucose in urine, and poison pair effect is little.
The present invention is made by raw material of Chinese medicine and Western medicine:
Wherein the percentage by weight of Chinese medicine is:
Radix Panacis Quinquefolii: 3-10 Rhizoma Coptidis: 10-40
The Radix Astragali: 10-40 Radix Salviae Miltiorrhizae: 10-40
Radix Puerariae: 5-30 Rhizoma Polygonati: 10-30
Radix Trichosanthis: 10-30
Glibenclamide by every day dosage be the 2.5-15 milligram
Each amounts of components for preparing 1000 capsules is:
Radix Panacis Quinquefolii 66.7g Radix Astragali 400g Rhizoma Coptidis 400g
Rhizoma Polygonati 200g Radix Trichosanthis 200g Radix Puerariae 200g
Radix Salviae Miltiorrhizae 200g glibenclamide 0.5g
Its processing and fabricating method following (prescription with above-mentioned preparation 1000 capsules is an example):
More than eight the flavor medicines, Radix Panacis Quinquefolii and part Rhizoma Coptidis powder are broken into fine powder, sieve, residue Rhizoma Coptidis and the Radix Astragali, Rhizoma Polygonati, Radix Trichosanthis, Radix Puerariae, Radix Salviae Miltiorrhizae Six-element decoct with water secondary, and each 1.5 hours, collecting decoction, filter, be concentrated into relative density 1.25-1.30 (50-60 ℃), add Radix Panacis Quinquefolii and Rhizoma Coptidis fine powder, mixing, drying, be ground into middle powder, add glibenclamide and appropriate amount of starch, mixing, the Capsules of packing into goes out 1000 promptly.
The pharmacology of each medicine of distinguishing the flavor of and act on as follows:
Radix Panacis Quinquefolii: the root of Araliaceae Radix Panacis Quinquefolii has lung benefiting the moon, the effect of asthenic fire, promoting the production of body fluid to quench thirst clearly.
The Radix Astragali: the dry root of leguminous plant Radix Astagali or Radix Astragali has invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, the effect of expelling pus and promoting granulation.
Rhizoma Coptidis: the dry rhizome of ranunculaceae plant Rhizoma Coptidis, Coptis deltoidea C.Y.Cheng et Hsiao or Coptis Teeta Wall.Has heat clearing and damp drying, the effect of eliminating fire and detoxication.
Rhizoma Polygonati: the dry rhizome of liliaceous plant Yunnan Rhizoma Polygonati, Rhizoma Polygonati or Polygonatum cyrtonema Hua.Effect with boosting qi and nourishing yin, spleen invigorating, lung moistening, kidney tonifying.
Radix Salviae Miltiorrhizae: labiate, the dry root and rhizome of Radix Salviae Miltiorrhizae.Have stasis-dispelling and pain-killing, the latus rectum of invigorating blood circulation, the effect of the relieving restlessness that clears away heart-fire.
Radix Puerariae: leguminous plant, the dry root of Herba Gelsemii Elegantis or Radix Puerariae rattan.Have expelling pathogenic factors from muscles for reducing heat, promote the production of body fluid, rash, the effect of yang invigorating antidiarrheal.
Radix Trichosanthis: the dry root of cucurbitaceous plant Fructus Trichosanthis.Effect with clearing away heat and promoting production of body fluid, detumescence and apocenosis.
Glibenclamide (glyburide)
N-[2-[4-[[[(hexamethylene amino) carbonyl] amino] sulfonyl] phenyl] ethyl]-2-methoxyl group-5-chlorobenzamide, have hypoglycemic activity.
In this capsule, Radix Panacis Quinquefolii, Rhizoma Polygonati giving young employees remedial-courses in general knowledge and vocational skills gas the moon, but Radix Panacis Quinquefolii replenishing body fluid and clearing away heat pathogen, Rhizoma Polygonati can the dry nourishing kidney essence of lung moistening.Radix Astragali invigorating the spleen and replenishing QI to be ending frequent micturition, and Radix Trichosanthis, Radix Puerariae Yin-nourishing and body fluid promoting protect Jin Yin with heat clearing away, Rhizoma Coptidis clearing away stomach-heat, and the Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling improves blood circulation and diabetes height and coagulates high smectic attitude.All medicines cooperate, play compatibility glibenclamide in the merit side of boosting qi and nourishing yin, clearing heat and moistening dryness, blood circulation promoting and blood stasis dispelling, blood sugar lowering altogether, can directly stimulate the beta Cell of islet excreting insulin, strengthen Insulin receptor INSR and postreceptor defects in the surrounding tissue, thereby the intensifier target histiocyte is to the sensitivity of insulin, i.e. the outer blood sugar reducing function of pancreas.The independent usefulness of glibenclamide easily causes side effect such as hypoglycemia, dyspepsia, diarrhea, cervicodynia, leukopenia.
This capsule is through 120 routine systematic observations, and its blood sugar lowering curative effect obviously is better than matched group glyburide and diabetes pill, and its obvious effective rate reaches 54.17%, total effective rate is 95%, and the glyburide obvious effective rate is 46.67%, and total effective rate is 86.67%, the diabetes pill obvious effective rate is 36.67%, and total effective rate is 80%.
This capsule only has an example than the hypopathia people comparatively slight hypoglycemic reaction to take place in 120 observed routine cases, and medicine decrement button recovers.And 2 routine hypoglycemic reactions appear in glyburide (glibenclamide) group 30 examples.One routine severe hypoglycemia reaction has appearred in diabetes pill group 30 examples.Prove that thus the probability of Tang Wei capsule generation hypoglycemic reaction and degree are well below glyburide (glibenclamide) and diabetes pill.
This capsule all can be alleviated or eliminate mouth rapidly and drinks polydipsia in 120 examples are observed, symptoms such as polyuria, polyphagia, weak, spontaneous sweating, dysphoria with feverish sensation in the chest palms and soles, and effect is lasting, and just tongue fur pulse condition improvement, its effect is better than diabetes pill and glyburide matched group.
Contain seven flavor Chinese medicine and Western medicine glyburide (glibenclamide) such as Radix Panacis Quinquefolii, Rhizoma Coptidis in this capsule.Clinical effectiveness proves that this medicine ratio is used Western medicine (glibenclamide) and Chinese medicine (removing the Chinese medicine part of glibenclamide) curative effect height separately, effect is fast, and side effect is little.Compare with similar kind diabetes pill, curative effect is higher than diabetes pill, and side effect is littler than diabetes pill.
This medicine is not found any infringement to internal organs such as patient's the heart, Liver and kidney in observed 120 examples.
Advantage of the present invention is that it is the specific drug of treatment type (type of deficiency of both QI and YIN), has characteristics rapid-action, that effect is strong, curative effect is high, toxic and side effects is little, the condition of illness elimination is fast.
Be embodiments of the invention below:
Embodiment 1:
Each amounts of components is: Radix Panacis Quinquefolii 1g, Rhizoma Coptidis 6g, Radix Astragali 6g, Radix Salviae Miltiorrhizae 6g, Radix Puerariae 3g, Rhizoma Polygonati 3g, Radix Trichosanthis 3g, glibenclamide 7.5mg.
Embodiment 2:
Each amounts of components is: Radix Panacis Quinquefolii 0.84g, Rhizoma Coptidis 2.8g, Radix Astragali 2.8g, Radix Salviae Miltiorrhizae 3.36g, Radix Puerariae 1.4g, Rhizoma Polygonati 8.4g, Radix Trichosanthis 8.4g, glibenclamide 7.5mg.

Claims (2)

1. hypoglycemic compound capsule for the treatment of diabetes is characterized in that being made by raw material of Chinese medicine and Western medicine:
Wherein the percentage by weight of Chinese medicine is:
Radix Panacis Quinquefolii: 3-10 Rhizoma Coptidis: 10-40
The Radix Astragali: 10-40 Radix Salviae Miltiorrhizae: 10-40
Radix Puerariae: 5-30 Rhizoma Polygonati: 10-30
Radix Trichosanthis: 10-30
Glibenclamide by every day dosage be the 2.5-15 milligram
2. hypoglycemic compound capsule according to claim 1 is characterized in that each amounts of components for preparing 1000 capsules is:
Radix Panacis Quinquefolii 66.7g Radix Astragali 400g Rhizoma Coptidis 400g
Rhizoma Polygonati 200g Radix Trichosanthis 200g Radix Puerariae 200g
Radix Salviae Miltiorrhizae 200g glibenclamide 0.5g
CN94101219A 1994-02-04 1994-02-04 Hypoglycemic compound capsule Expired - Fee Related CN1066332C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN94101219A CN1066332C (en) 1994-02-04 1994-02-04 Hypoglycemic compound capsule

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN94101219A CN1066332C (en) 1994-02-04 1994-02-04 Hypoglycemic compound capsule

Publications (2)

Publication Number Publication Date
CN1107711A CN1107711A (en) 1995-09-06
CN1066332C true CN1066332C (en) 2001-05-30

Family

ID=5030052

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94101219A Expired - Fee Related CN1066332C (en) 1994-02-04 1994-02-04 Hypoglycemic compound capsule

Country Status (1)

Country Link
CN (1) CN1066332C (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100335080C (en) * 2003-12-12 2007-09-05 陈永军 Medication for treating diabetes
CN1305506C (en) * 2005-10-17 2007-03-21 高春 Chinese medicinal pill for treating diabetes mellitus
CN100364559C (en) * 2005-11-22 2008-01-30 余内逊 Method for preparing oral liquid of several micron powders for reducing blood sugar and anti-fatigue
CN103340261A (en) * 2013-06-21 2013-10-09 庞朝成 Selenium-rich radix pueraiae bee pollen tea
CN103651974A (en) * 2013-11-22 2014-03-26 安徽大平油脂有限公司 Health oil with efficacy of decreasing blood sugar
CN104367637A (en) * 2014-11-06 2015-02-25 华洪萍 Traditional Chinese medicine used for treating type 2 diabetes
CN107441334A (en) * 2017-08-11 2017-12-08 成都风靡生物科技有限公司 A kind of Chinese medicine composition for treating deficiency of both qi and yin with blood stasis type type II diabetes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1066602A (en) * 1992-05-08 1992-12-02 王德修 The compound method of hypoglycemic compound capsule

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1066602A (en) * 1992-05-08 1992-12-02 王德修 The compound method of hypoglycemic compound capsule

Also Published As

Publication number Publication date
CN1107711A (en) 1995-09-06

Similar Documents

Publication Publication Date Title
CN1240416C (en) Medicine for curing hypertension and its preparation method
CN1872180A (en) Medication of membranous milk vetch for activating blood and the channels, and preparation method
CN101856405B (en) Medicinal composition for treating type II diabetes mellitus and preparation method thereof
CN1301737C (en) Chinese medicinal preparation for treating diabetes and its preparation method
CN1066332C (en) Hypoglycemic compound capsule
CN1947778A (en) Hypoglycemic medicine preparation and its prepn. method
CN1159050C (en) Composite Chinese medicine prepn for treating type II diabetes
CN101279034B (en) Combined Chinese medicament for curing diabetic with combined internal and external therapies and preparation thereof
CN1879783A (en) A medicine for treating diabetes
CN1285367C (en) Medicinal preparation for treating diabetes and its preparation method
CN103393938B (en) Traditional Chinese medicine composition for reducing blood sugar
CN1202847C (en) Diabetes treating medicine
CN1245197C (en) Chinese medicine preparation for treating coronary heart disease and viral myocarditis
CN1053111C (en) Chinese medical composite preparation with such functions as dispelling toxicity, detoxicating, recuperating, health preserving and face nursing
CN1054524C (en) Medicinal composition for treating diabetes involving upper jiao
CN1054525C (en) Medicinal composition for treating diabetes involving lower jiao
CN1223368C (en) Capsules for nourishing yin and reducing blood sugar
CN1076622C (en) Chinese medicine for curing nephritis
CN1864728A (en) Prescription and preparation method of yin-nourishing capsule containing ginseng and astragalus root
CN1168483C (en) Heart disease treating medicine
CN1879753A (en) Medicine for treating diabetes of blood stasis complicated kidney spleen deficiency type
CN1306830A (en) Medicine for treating Type-11 diabetes
CN1602921A (en) Medicine for treating diabetes and its preparing process
CN1058403C (en) Medicinal composition for treating diabetes involving middle jiao
CN1313128A (en) Chinese-medicinal capsule for treating diabetes and its preparing process

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: HEBEI PROVINCE CANGZHOU TANGSHENG PHARMACEUTICAL C

Free format text: FORMER NAME OR ADDRESS: CANGZHOU CHINESE-MEDICINAL PHARMACEUTICAL FACTORY, HEBEI PROV.

CP01 Change in the name or title of a patent holder

Patentee after: Cangzhou Hebei Tang Sheng Pharmaceutical Co., Ltd.

Patentee before: Cangzhou Chinese-Medicinal Pharmaceutical Factory, Hebei Prov.

ASS Succession or assignment of patent right

Owner name: SUNNYTWAY PHARMACEUTICAL CO., LTD. HEBEI

Free format text: FORMER OWNER: TANGSHENG PHARMACEUTICAL CO., LTD. CANGZHOU, HEBEI

Effective date: 20100802

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 061000 NO.8, SOUTH SECTION, JINDE HIGHWAY, CANGZHOU CITY, HEBEI PROVINCE TO: 061000 NO.9, JINGUANG STREET, DEVELOPMENT ZONE, CANGZHOU CITY, HEBEI PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20100802

Address after: 061000 No. nine, golden light street, Cangzhou Development Zone, Hebei

Patentee after: Sunnytway Pharmaceutical Co., Ltd. Hebei

Address before: 061000 Cangzhou city of Hebei Province Jin De South Highway No. 8

Patentee before: Cangzhou Hebei Tang Sheng Pharmaceutical Co., Ltd.

ASS Succession or assignment of patent right

Owner name: BAISHAN TANGWEI (CANGZHOU) PHARMACEUTICAL CO., LTD

Free format text: FORMER OWNER: SUNNYTWAY PHARMACEUTICAL CO., LTD. HEBEI

Effective date: 20120121

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20120121

Address after: 061000 Cangzhou economic and Technological Development Zone, Hebei, No. nine main street

Patentee after: Baishan Tang Wei (Cangzhou) Pharmaceutical Co. Ltd.

Address before: 061000 No. nine, golden light street, Cangzhou Development Zone, Hebei

Patentee before: Sunnytway Pharmaceutical Co., Ltd. Hebei

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20010530

Termination date: 20120204